Getting your player ready...
WASHINGTON — A federal health panel on Thursday said a highly anticipated bone drug from Amgen benefits patients with osteoporosis but should not be used to prevent the disease because of long-term safety questions.
Food and Drug Administration experts unanimously voted that Amgen’s injectable drug denosumab helps prevent bone fractures in women with postmenopausal osteoporosis.
